Biodegradable lipids for the delivery of active agents

US11633480B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11633480-B2
Application numberUS-202217651023-A
CountryUS
Kind codeB2
Filing dateFeb 14, 2022
Priority dateDec 7, 2011
Publication dateApr 25, 2023
Grant dateApr 25, 2023

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.

First claim

Opening claim text (preview).

What is claimed is: 1. A lipid particle comprising: (i) a nucleic acid, (ii) 35-65 mol % of a protonatable lipid compound, (iii) 3-12 mol % distearoylphosphatidylcholine (DSPC), (iv) 15-45 mol % cholesterol, and (v) 0.5-10 mol % of a PEG-modified lipid, wherein the mol % is based on 100% total moles of lipids in the lipid particle, wherein the protonatable lipid compound comprises a head group, hydrophobic tails, and a central moiety to which the head group and the hydrophobic tails are directly bonded, wherein: the central moiety is a nitrogen atom; the hydrophobic tails consist of two hydrophobic tails; each of the two hydrophobic tails has the formula —R 12 -M 1 -R 13 , wherein R 12 is a C 4 -C 14 alkyl group, M 1 is a —OC(O)— group, and R 13 is a C 10 -C 20 branched alkyl group; the chain length of formula —R 12 -M 1 -R 13 is at most 21 atoms; and the total carbon atom content of each hydrophobic tail is 21 to 26 carbon atoms. 2. The lipid particle of claim 1 , wherein R 13 is branched at the alpha position relative to the —OC(O)— group. 3. The lipid particle of claim 2 , wherein the chain length of formula —R 12 -M 1 -R 13 is 17 atoms. 4. The lipid particle of claim 2 , wherein the nucleic acid comprises RNA. 5. A lipid particle comprising: (i) a nucleic acid, (ii) 35-65 mol % of a protonatable lipid compound, (iii) 3-12 mol % distearoylphosphatidylcholine (DSPC), (iv) 15-45 mol % cholesterol, and (v) 0.5-10 mol % of a PEG-modified lipid, wherein the PEG-modified lipid is 1-(monomethoxy-polyethylene glycol)-2,3-dimyristoyl glycerol (PEG-DMG), wherein the mol % is based on 100% total moles of lipids in the lipid particle, wherein the protonatable lipid compound comprises a head group, hydrophobic tails, and a central moiety to which the head group and the two hydrophobic tails are directly bonded, wherein: the central moiety is a nitrogen atom; the hydrophobic tails consist of two hydrophobic tails; each of the two hydrophobic tails independently consists of a first hydrophobic chain, an ester group, and a second hydrophobic chain, wherein the first and second hydrophobic chains are aliphatic and linked by the ester group, and the first hydrophobic chain is bonded directly to the central moiety, wherein each ester group is —C(O)O—; wherein each hydrophobic tail has a total carbon atom content from 17 to 26 carbon atoms; and wherein one hydrophobic tail has the formula: wherein R 13 is a C 13 -C 17 branched alkyl; and the chain length of the one hydrophobic tail is from 18 to 20 atoms. 6. The lipid particle of claim 5 , wherein, R 13 is a C 17 branched alkyl. 7. The lipid particle of claim 6 , wherein the hydrophobic tail having the formula: has a chain length of 18 atoms. 8. The lipid particle of claim 5 , wherein R 13 is branched at the alpha position relative to the —C(O)O— group. 9. The lipid particle of claim 8 , wherein the nucleic acid comprises RNA. 10. The lipid particle of claim 8 , wherein the head group consists of a saturated aliphatic group and a hydroxyl group. 11. The lipid particle of claim 2 , wherein the head group consist of a saturated aliphatic group and a hydroxyl group. 12. A method for preparing a lipid particle mixture comprising mixing a first solution comprising an organic solvent, a protonatable lipid compound, distearoylphosphatidylcholine (DSPC), cholesterol, and a PEG-modified lipid, with a second solution comprising a nucleic acid and water to form a lipid particle mixture, wherein the lipid particle comprises (i) the nucleic acid, (ii) 35-65 mol % of the protonatable lipid compound, (iii) 3-12 mol % distearoylphosphatidylcholine (DSPC), (iv) 15-45 mol % cholesterol, and (v) 0.5-10 mol % of the PEG-modified lipid, wherein the mol % is based on 100% total moles of lipids in the lipid particle, wherein the protonatable lipid compound comprises a head group, hydrophobic tails, and a central moiety to which the head group and the hydrophobic tails are directly bonded, wherein: the central moiety is a nitrogen atom; the hydrophobic tails consist of two hydrophobic tails, each of the two hydrophobic tails has the formula —R 12 -M 1 -R 13 wherein R 12 is a C 4 -C 14 alkyl group, M 1 is a —OC(O)—, and R 13 is a C 10 -C 20 branched alkyl group; the chain length of formula —R 12 -M 1 -R 13 is at most 21 atoms; and the total carbon atom content of each hydrophobic tail is 21 to 26 carbon atoms. 13. The method of claim 12 , wherein R 13 is branched at the alpha position relative to the —OC(O)— group. 14. The method of claim 13 , wherein the organic solvent comprises ethanol and the second solution comprises an aqueous buffer. 15. The method of claim 14 , wherein the aqueous buffer is a citrate buffer. 16. The method of claim 15 , further comprising dialyzing or diafiltering the lipid particle mixture. 17. The method of claim 13 , wherein the nucleic acid comprises RNA. 18. The method of claim 13 , wherein the chain length of formula —R 12 -M 1 -R 13 is 17 atoms. 19. The method of claim 13 , wherein the head group consists of a saturated aliphatic group and a hydroxyl group. 20. A method for preparing a lipid particle mixture comprising mixing a first solution comprising an organic solvent, a protonatable lipid compound, distearoylphosphatidylcholine (DSPC), cholesterol, and a PEG-modified lipid, with a second solution comprising a nucleic acid and water to form a lipid particle mixture, wherein the lipid particle comprises (i) a nucleic acid, (ii) 35-65 mol % of a protonatable lipid compound, (iii) 3-12 mol % distearoylphosphatidylcholine (DSPC), (iv) 15-45 mol % cholesterol, and (v) 0.5-10 mol % of the PEG-modified lipid, wherein the PEG-modified lipid is 1-(monomethoxy-polyethylene glycol)-2,3-dimyristoyl glycerol (PEG-DMG), wherein the mol % is based on 100% total moles of lipids in the lipid particle, wherein the protonatable lipid compound comprises a head group, hydrophobic tails, and a central moiety to which the head group and the hydrophobic tails are directly bonded, wherein: the central moiety is a nitrogen atom; the hydrophobic tails consist of two hydrophobic tails; each of the two hydrophobic tails independently consists of a first hydrophobic chain, an ester group, and a second hydrophobic chain, wherein the first and second hydrophobic chains are aliphatic and linked by the ester group, and the first hydrophobic chain is bonded directly to the central moiety, wherein each ester group is —C(O)O—; wherein each hydrophobic tail has a total carbon atom content from 17 to 26 carbon atoms; and wherein one hydrophobic tail has the formula: wherein: R 13 is a C 13 -C 17 branched alkyl; and the chain length of the one hydrophobic tail is from 18 to 20 atoms. 21. The method of claim 20 , wherein R 13 is a C 17 branched alkyl. 22. The method of claim 21 , wherein the hydrophobic tail having the formula: has a chain length of 18 atoms. 23. The method of claim 20 , wherein R 13

Assignees

Inventors

Classifications

  • Diaminoethanes · CPC title

  • the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom · CPC title

  • substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title

  • Organic compounds, e.g. fats, sugars · CPC title

  • with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11633480B2 cover?
The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggreg…
Who is the assignee on this patent?
Alnylam Pharmaceuticals Inc
What technology area does this patent fall under?
Primary CPC classification A61K47/18. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).